Therefore, in cases where SGLT2 inhibitors are used in conditions with decreased insulin secretion, including type 1 diabetes, it is necessary to pay attention not only to blood sugar but also to changes in body composition, including muscle mass and bone mineral density [46]. Here, SLC5A2 is linked to type 1 diabetes mellitus.